NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Xenocor

Xenocor

Private
Salt Lake City, UtahHealthcare & Life Scienceshttps://xenocor.com/

Last Round

Series A

Apr 18, 2023

Total Funding Raised

$10M

Momentum

Top 10%

of companies Caplight tracks

Company Overview

Xenocor is a medical device company that develops and markets single-use, high-definition, fog-free laparoscopic imaging systems for minimally invasive surgical procedures.

Sector

Healthcare & Life Sciences

Verticals

Medical Devices, Medical Imaging

Business Model

B2B

Customer Profile

Hardware Sales

AI Layer

Non-AI

Keywords

surgical visualizationminimally invasive surgerylaparoscopemedical devicesurgical imagingdisposable laparoscopeendoscopysingle-use medical devicessurgical hardwarevideo processorambulatory surgery centerASCoperating room equipmentsurgical techmedtech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Xenocor Comparables

Compare Xenocor with similar companies based on industry and business-model similarity.

Xenocor comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Outlook Surgical
86%
Contra Healthcare Solutions
80%
Pristine Surgical
77%

Xenocor Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
Series AApr 18, 2023
StrategicJun 22, 2021
AcceleratorJun 15, 2021
Series A ExtensionApr 27, 2021
VC RoundOct 5, 2020

Key People

Founding team and executive leadership

David McNally

Chief Executive Officer

Executive Team

Tony Watson

Chief Commercial Officer, Chief Operating Officer

Executive Team

Xenocor Investors

Notable investors and investment history

Xenocor investors
InvestorRounds
GenHenn CapitalSeries A
MedTech InnovatorAccelerator
Mountain Pacific Venture FundVC Round
Patel Family InvestmentsSeries A
Growing Impact VenturesSeries A Extension

Market signals

Structured signals derived from secondary market and firmographic data.

  • May 17, 2026

    Grew 33% QoQ from 9 to 12 employees.

  • Apr 28, 2026

    Grew 50% QoQ, from 8 to 12 employees.

Xenocor Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Xenocor Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Xenocor's valuation, stock price, and market status.

Firmographic Details

HeadquartersSalt Lake City, Utah
Employee Range12
Year Founded2014
Last FundingApr 18, 2023

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.